KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Vertex Pharmaceuticals (VRTX) Research & Development (2016 - 2025)

Historic Research & Development for Vertex Pharmaceuticals (VRTX) over the last 17 years, with Q3 2025 value amounting to $977.7 million.

  • Vertex Pharmaceuticals' Research & Development rose 1162.23% to $977.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.9 billion, marking a year-over-year increase of 1383.89%. This contributed to the annual value of $3.6 billion for FY2024, which is 1477.76% up from last year.
  • Vertex Pharmaceuticals' Research & Development amounted to $977.7 million in Q3 2025, which was up 1162.23% from $978.4 million recorded in Q2 2025.
  • Vertex Pharmaceuticals' 5-year Research & Development high stood at $998.7 million for Q4 2024, and its period low was $448.7 million during Q2 2021.
  • For the 5-year period, Vertex Pharmaceuticals' Research & Development averaged around $747.8 million, with its median value being $785.7 million (2023).
  • As far as peak fluctuations go, Vertex Pharmaceuticals' Research & Development crashed by 536.92% in 2021, and later soared by 3811.56% in 2022.
  • Vertex Pharmaceuticals' Research & Development (Quarter) stood at $567.8 million in 2021, then increased by 22.24% to $694.1 million in 2022, then increased by 18.8% to $824.6 million in 2023, then grew by 21.11% to $998.7 million in 2024, then decreased by 2.1% to $977.7 million in 2025.
  • Its last three reported values are $977.7 million in Q3 2025, $978.4 million for Q2 2025, and $979.7 million during Q1 2025.